Failure to Obtain Medication-Specific Informed Consent for Psychotropic Drugs
Summary
The facility failed to obtain informed consent and failed to ensure residents or their resident representatives were informed in advance of the risks, benefits, and treatment alternatives for psychotropic medications for 4 of 4 residents reviewed. The record review and interviews showed that the facility relied on general psychotropic medication consent forms signed on admission, but those forms did not document medication-specific risks, benefits, or alternatives for the antipsychotic medications being administered. The Medical Director stated that informed consent was not completed when residents were admitted already receiving psychotropic medications, and the DON and Administrator stated they believed the psychiatric providers were responsible for explaining the risks and benefits. Resident #1 had Parkinson's disease, dementia with behavioral disturbance, anxiety, and depression, and had an active order for quetiapine fumarate at bedtime. The EMR contained no documented evidence that the resident or RR were informed in advance of the risks, benefits, and alternatives for quetiapine fumarate. The only consent in the record was a general psychotropic medication consent signed on admission, and the RR stated she was not notified by the facility about the risks, benefits, or treatment alternatives and reported the medication was prescribed by the resident's neurologist. Resident #2 had Lewy body neurocognitive disorder, dementia with psychotic disturbance, depression, and Parkinson's disease, and had an active order for pimavanserin tartrate daily; the record likewise contained no documented evidence of advance informed consent specific to that medication. Resident #62 had dementia, anxiety, and depression, and had an active order for aripiprazole daily. The EMR showed no documented evidence that the resident representative was informed in advance of the risks, benefits, and treatment alternatives for aripiprazole, and the only consent was a general psychotropic medication form signed on admission. Resident #46 had Parkinson's disease, schizoaffective disorder, and bipolar disorder with severe psychotic features, and had an active order for risperidone twice daily. The EMR contained no documented evidence that the Guardian was informed in advance of the risks, benefits, and treatment alternatives for risperidone, and the Guardian stated she had not signed an informed consent form for the antipsychotic medication until the facility contacted her on 5/20/26 to request her signature.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.